KBY Biotech Indexv0.0.34
Search
← Pipeline|ASA-IIT-161

ASA-IIT-161

Phase 3
By Asan Medical Center
Source: Trial-derived·Trials: 1
Modality
Nanobody
MOA
CDK4/6i
Target
MDM2
Pathway
Checkpoint
Huntington's
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
~Oct 2021
→ ~Jan 2023
Phase 3
Apr 2023
→ Mar 2025
Phase 3Current
NCT08185282
1,678 pts·Huntington's
2023-04→2025-03·Active
1,678 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-121.1y agoPh3 Readout· Huntington's
2026-10-096mo awayEMA Filing· Huntington's
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P3
Active
Catalysts
Ph3 Readout
2025-03-12 · 1.1y ago
Huntington's
EMA Filing
2026-10-09 · 6mo away
Huntington's
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08185282Phase 3Huntington'sActive1678SeizFreq
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5767PfizerPhase 1/2BETCDK4/6i
LLY-6079Eli LillyPhase 2MDM2PRMT5i
LLY-3251Eli LillyPhase 2MDM2BiTE
RHH-1969RocheApprovedBETCDK4/6i
IvocapivasertibBristol-Myers SquibbPhase 1BETCDK4/6i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
FixatenlimabGSKPhase 1/2JAK1CDK4/6i
GSK-7987GSKPhase 3MDM2PD-1i
AMG-2752AmgenPreclinicalMDM2WRNi
REG-3155RegeneronPhase 1/2MDM2PI3Ki